Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Incyte Corporation |
---|---|
Information provided by: | Incyte Corporation |
ClinicalTrials.gov Identifier: | NCT00698230 |
Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.
Condition | Intervention | Phase |
---|---|---|
Type 2 Diabetes |
Drug: INCB013739 Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized Study to Evaluate the Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetic Subjects |
Estimated Enrollment: | 300 |
Study Start Date: | May 2008 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Dose 1 INCB013739
|
Drug: INCB013739
INCB013739 tablet form
|
2: Experimental
Dose 2 INCB013739
|
Drug: INCB013739
INCB013739 tablet form
|
3: Experimental
Dose 3 INCB013739
|
Drug: INCB013739
INCB013739 tablet form
|
4: Experimental
Dose 4 INCB013739
|
Drug: INCB013739
INCB013739 tablet form
|
5: Experimental
Dose 5 INCB013739
|
Drug: INCB013739
INCB013739 tablet form
|
6: Placebo Comparator |
Drug: Placebo
Placebo Tablet
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Incyte Corporation ( Pam Murphy, VP Investor Relations and Corporate Communication ) |
Study ID Numbers: | INCB 13739-202 |
Study First Received: | June 13, 2008 |
Last Updated: | April 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00698230 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hypoglycemic Agents Metabolic Diseases Metformin Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Hypoglycemic Agents Metabolic Diseases Physiological Effects of Drugs Metformin Diabetes Mellitus, Type 2 |
Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Pharmacologic Actions |